We are live on ! Find out more
IFRX icon

InflaRx

27 hedge funds and large institutions have $7.63M invested in InflaRx in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more call options, than puts

Call options by funds: $6K | Put options by funds: $1K

2.68% less ownership

Funds ownership: 14.59%11.9% (-2.7%)

16% less funds holding

Funds holding: 3227 (-5)

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

36% less capital invested

Capital invested by funds: $12M → $7.63M (-$4.35M)

38% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 13

Holders
27
Holders Change
-5
Holders Change %
-15.63%
% of All Funds
0.45%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
5
Reduced
6
Closed
13
Calls
$6K
Puts
$1K
Net Calls
+$5K
Net Calls Change
-$50K

IFRX Hedge Fund Activity: Q2 2022 in Review

27 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in InflaRx (IFRX) for Q2 2022, worth a combined $7.63M — down 36% from $12M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of IFRX and 8 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 5 added.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $71K. The largest seller was Ikarian Capital, exiting entirely with an estimated $639K sold.

  • 27 institutional investors held InflaRx (IFRX) as of Q2 2022, down from 32 in Q1 2022.
  • Funds reported $7.63M of InflaRx stock for Q2 2022, down 36% quarter-over-quarter.
  • 8 funds opened new InflaRx positions in Q2 2022 and 13 closed out, a net change of -5 holders.
  • The largest InflaRx buyer in Q2 2022 was Susquehanna International Group, an estimated $71K added.
  • The largest InflaRx seller in Q2 2022 was Ikarian Capital, an estimated $639K sold.

Based on aggregated 13F filings for Q2 2022.